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HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection. 
The risk of developing TB is between 20 and 37 times 
greater in people living with HIV than among those 
who do not have HIV infection. TB is responsible 
for more than a quarter of deaths in people living 
with HIV. Relatively more women than men were 
detected to have TB in countries with a prevalence 
of HIV infection of more than 1%. In response to 
the dual epidemics of HIV and TB, the World 
Health Organization (WHO) has recommended 12 
collaborative TB/HIV activities as part of core HIV 
and TB prevention, care and treatment services. 
They include interventions that reduce the morbidity 
and mortality from TB in people living with HIV, such 
as the provision of antiretroviral therapy (ART) and 
the Three I’s for HIV/TB: intensified case-finding of 
TB (ICF), isoniazid preventive therapy (IPT), and 
infection control for TB.
On 25–27 January 2010, WHO conducted a global 
policy meeting to review the evidence regarding ICF 
and IPT, and to reconceptualize the 1998 WHO/
Joint United Nations Programme on HIV/AIDS 
(UNAIDS) Policy on TB prevention.  Key questions 
were identified and a comprehensive review of 
the available scientific evidence was conducted to 
formulate the recommendations. The evidence was 
evaluated using the Grading of Recommendations 
Assessment, Development and Evaluation 
(GRADE) criteria. The quality of the evidence was 
categorized as high (when further research is very 
unlikely to change our confidence in the estimate 
of effect), moderate (further research is likely to 
have an important impact on our confidence in the 
effect) and low (further research is very likely to 
have an estimate of effect and is likely to change the 
estimate). Reports were also commissioned from 
people living with HIV and affected communities 
regarding the key questions and the summary of the 
evidence. After the initial draft was reviewed by the 
Guidelines Group, the comments were incorporated 
into a draft that was then sent to over 200 people 
for peer review. Comments from around 30 internal 
and external peer reviewers were used to finalize 
the recommendations. The final recommendations 
take into consideration the quality of evidence, 
cost, feasibility, and values and preferences of 
the community and health-care workers. The 
recommendations were classified as strong 
when the guidelines group was confident that the 
desirable effects of adherence to a recommendation 
outweigh the undesirable effects, and as conditional 
(weak) when the desirable effects of adherence to 
a recommendation probably outweigh the effects, 
but the panel was not confident about these trade-
offs. These new guidelines recommend the use 
of a simplified screening algorithm that relies on 
four clinical symptoms to identify those eligible for 
either IPT or further diagnostic work-up for TB and 
other conditions. Chest radiography is no longer 
a mandatory investigation before starting IPT. In 
contrast to the 1998 Policy, the new guidelines 
strongly recommend at least six months of IPT for 
children and adults including pregnant women, 
people living with HIV, those receiving ART, and those 
who have successfully completed TB treatment. 
IPT for a duration of 36 months is conditionally 
recommended in settings with a high transmission 
of TB among people living with HIV. The revised 
guidelines also emphasize that a tuberculin skin 
test (TST) is not a requirement for initiating IPT in 
people living with HIV. However, in some settings 
where it is feasible, it can help to identify those who 
would benefit most from IPT. The guidelines also 
emphasize that IPT is a core component of HIV 
prevention and care, and should be the primary 
responsibility of AIDS programmes and HIV service 
providers. In addition, the provision of IPT should 
not be viewed as an isolated intervention for people 
living with HIV. Rather, it should be part of a TB 
prevention package along with infection control for 
TB, ICF and provision of ART. 
 Executive Summary
Executive summary
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Key recommendations 
Adults and adolescents living with HIV should be screened for TB with a 
clinical algorithm and those who do not report any one of the symptoms 
of current cough, fever, weight loss or night sweats are unlikely to have 
active TB and should be offered IPT. 
Adults and adolescents living with HIV and screened with a clinical 
algorithm for TB, and who report any one of the symptoms of current 
cough, fever, weight loss or night sweats may have active TB and 
should be evaluated for TB and other diseases. 
Adults and adolescents living with HIV who have an unknown or 
positive TST status and are unlikely to have active TB should receive 
at least six months of IPT as part of a comprehensive package of HIV 
care. IPT should be given to such individuals irrespective of the degree 
of immunosuppression, and also to those on ART, those who have 
previously been treated for TB and pregnant women.
Adults and adolescents living with HIV who have an unknown or positive 
TST status and who are unlikely to have active TB should receive at least 
36 months of IPT.2 IPT should be given to such individuals irrespective of 
the degree of immunosuppression, and also to those on ART, those who 
have previously been treated for TB and pregnant women. 
TST is not a requirement for initiating IPT in people living with HIV. 
People living with HIV who have a positive TST benefit more from IPT; 
TST can be used where feasible to identify such individuals. 
Strong recommendation, moderate quality of evidence1
Strong recommendation, moderate quality of evidence
Strong recommendation, high quality of evidence
Conditional recommendation, moderate quality of evidence3
Strong recommendation, moderate quality of evidence
Strong recommendation, high quality of evidence
1
2
3
4
5
6
1 A strong recommendation is one for which the panel is confident that the desirable effects of adherence to a recommendation 
outweigh the undesirable effects. 
2 The considerations for implementation should include the local context such as the epidemiology of TB and HIV, and settings with 
the highest rates of prevalence and transmission of TB among people living with HIV.
3 A conditional recommendation is one for which the panel concludes that the desirable effects of adherence to a recommendation 
probably outweigh the undesirable effects and data to support the recommendation are scant. Therefore, the recommendation is 
only applicable to a specific group, population or setting, or new evidence may result in changing the balance of risk to benefit, or the 
benefits may not warrant the cost or resource requirements in all settings.
vi
4 Poor weight gain is defined as reported weight loss, or very low weight (weight-for-age less than –3 z-score), or underweight (weight-
for-age less than –2 z-score), or confirmed weight loss (>5%) since the last visit, or growth curve flattening,
Providing IPT to people living with HIV does not increase the risk of 
developing isoniazid (INH)-resistant TB. Therefore, concerns regarding 
the development of INH resistance should not be a barrier to providing 
IPT.
Children living with HIV who do not have poor weight gain,4 fever or 
current cough are unlikely to have active TB.
Children living with HIV who have any one of the following symptoms 
– poor weight gain, fever, current cough or contact history with a 
TB case – may have TB and should be evaluated for TB and other 
conditions. If the evaluation shows no TB, such children should be 
offered IPT regardless of their age. 
Children living with HIV who are more than 12 months of age and who 
are unlikely to have active TB on symptom-based screening, and have 
no contact with a TB case should receive six months of IPT (10 mg/kg/
day) as part of a comprehensive package of HIV prevention and care 
services.
In children living with HIV who are less than 12 months of age, only 
those children who have contact with a TB case and who are evaluated 
for TB (using investigations) should receive six months of IPT if the 
evaluation shows no TB disease.
All children living with HIV who have successfully completed treatment 
for TB disease should receive INH for an additional six months. 
Strong recommendation, moderate quality of evidence
Strong recommendation, low quality of evidence
Strong recommendation, low quality of evidence
Strong recommendation, moderate quality of evidence
Strong recommendation, low quality of evidence
Conditional recommendation, low quality of evidence
7
8
9
10
11
12
Key recommendations
vii
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1
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection. 
The risk of developing TB is between 20 and 37 times 
greater in people living with HIV than among those 
who do not have HIV infection.[1] TB is responsible 
for more than a quarter of deaths among people living 
with HIV.[2]  Relatively more women than men were 
detected to have TB in countries with a prevalence 
of HIV infection of more than 1%.[1] In response 
to the dual epidemics of HIV and TB, the World 
Health Organization (WHO) has recommended 12 
collaborative TB/HIV activities as part of core HIV 
and TB prevention, care and treatment services.[3] 
These include interventions that reduce the morbidity 
and mortality from TB in people living with HIV, such 
as the provision of antiretroviral therapy (ART) and 
the Three I’s for HIV/TB: intensified case-finding of 
TB (ICF), isoniazid preventive therapy (IPT) and 
infection control for TB.[4]  
A high rate of previously undiagnosed TB is common 
among people living with HIV.[5,6] ICF and treatment 
of TB among people living with HIV interrupts disease 
transmission by infectious cases,[7,8] reduces 
morbidity and delays mortality.[9] Most importantly, 
active screening for TB offers the opportunity to 
provide preventive therapy for those who do not have 
symptoms and signs of TB.[10] 
IPT is a key public health intervention for the 
prevention of TB among people living with HIV and 
has been recommended since 1998 by WHO and 
the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) as part of a comprehensive HIV and AIDS 
care strategy.[11] It has subsequently been included in 
a number of WHO guidelines and recommendations.
[3,12] However, its implementation has been very 
slow and has been impeded by several barriers 
including lack of an accepted approach to exclude 
active TB disease and restricted access to isoniazid 
for fear of developing drug resistance. By the end 
of 2009, globally only 85 000 people living with HIV 
received IPT.[1] It is not known what proportion of 
these were children. 
In April 2008, WHO convened the Three I’s for HIV/
TB Meeting, which called for a re-conceptualization 
of the existing WHO/UNAIDS Policy on IPT to reflect 
new scientific evidence and thinking about HIV and 
TB prevention, care and treatment, and expedite 
the implementation of this important intervention in 
tandem with ICF.[4] Therefore, the objective of these 
guidelines is to provide guidance for national TB 
and AIDS programmes by updating existing WHO 
recommendations with new evidence, taking into 
consideration the changing context of HIV and TB 
prevention, treatment and care. The new guidelines 
focus on facilitating the implementation of IPT and 
ICF. The guidelines are also intended to highlight 
and strengthen the leadership role of national AIDS 
programmes and HIV stakeholders to scale up the 
implementation of TB screening and provision of IPT 
among people living with HIV.   
1. Background and process
1.1 Background
1.2 Target audience
The guidelines are aimed at health-care workers providing care for people living with HIV, policy-makers and health programme 
managers working in the field of HIV/AIDS and 
TB. These guidelines are also intended for 
governments, nongovernmental organizations, 
donors and patient support groups that address 
HIV and TB.  
Background and process
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1.3 Scope
1.4 Process of formulating the guidelines 
1. What is the best combination of signs, symptoms 
and diagnostic procedures (e.g. smear 
microscopy, radiography, serum-based tests such 
as interferon-gamma release assays [IGRA]) that 
can be used as screening tools to determine 
the eligibility for treatment of latent TB infection 
(LTBI)?  
2. What is the optimal duration and drug regimen 
(e.g. INH, rifampicin, etc.) for treatment of LTBI to 
reduce the risk of developing TB among people 
living with HIV?
3. What is the optimal time to start considering 
initiation of IPT (i.e. should immune status be 
considered and should IPT be started with ART)?
4. Should secondary treatment of LTBI be provided 
for people living with HIV to prevent reinfection or 
recurrence of TB after successful completion of 
TB treatment?
5. Does treatment for LTBI among people living with 
HIV lead to significant development of mono-
resistance against the drug(s) used for LTBI 
treatment?
6. Will low adherence rates to treatment for LTBI be 
a barrier to the implementation of LTBI treatment 
among people living with HIV?
7. Is the provision of treatment for LTBI cost-
effective?
8. Is the use of tuberculin skin test (TST) feasible in 
resource-limited settings?
The guidelines include evidence-based 
recommendations for adults, children and infants, the 
summary and grading of evidence, implementation 
issues and key research gaps. In contrast to the 
1998 WHO/UNAIDS Policy, these new guidelines 
reconceptualize ICF and the provision of IPT as 
integral and interlinked components of quality care 
for people living with HIV. The revised guidelines 
recommend the use of an evidence-based, simplified 
TB screening algorithm that relies on four clinical 
symptoms to identify those eligible for either IPT or 
further diagnostic work-up for TB or other diseases. 
Although a subject of another set of WHO guidelines, 
screening for TB also allows for improved infection 
control measures to prevent nosocomial transmission. 
These guidelines also include recommendations for 
people living with HIV who are pregnant, on ART and 
have completed TB treatment. The guidelines will 
be reviewed and updated in five years according to 
WHO procedure.[13]
The guidelines present a set of recommendations that will help reduce TB disease in people living with 
HIV, their families and communities through a combination of screening for TB and provision of IPT. The 
following eight questions were used to guide the review of the evidence for developing the guidelines. 
As part of the Guideline Review Committee (GRC)-recommended process, the WHO HIV/AIDS and Stop TB Departments conducted 
a global policy meeting on 25–27 January 2010 to 
review the evidence regarding ICF and IPT, and to 
reconceptualize the 1998 WHO/UNAIDS Policy on 
TB prevention (Annexes 1–3). Key questions were 
identified and a comprehensive review of the available 
scientific evidence was conducted to formulate the 
recommendations. A WHO Guidelines Group to review 
the evidence and formulate the recommendations 
was established and a comprehensive review of the 
available scientific evidence for eight key questions 
(see above) was prepared. Systematic literature 
reviews of studies related to the eight questions 
among people living with HIV were conducted using 
PubMed, and various combinations of keywords were 
used to search for studies related to each question. A 
search was also conducted for abstracts presented at 
conferences on TB and lung disease organized by the 
International Union Against TB and Lung Disease (The 
Union) and the International AIDS Society between 
2000 and 2008. All retrieved titles and abstracts 
were reviewed for their relevance to the topic in the 
question. The reference lists of the retrieved studies 
were also reviewed to identify further studies that met 
the eligibility criteria. In addition, recognized experts in 
the field were contacted to identify studies that were 
not available (e.g. unpublished) in the initial electronic 
search for each question. 
The quality of evidence and strength of recommendation 
was assessed using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
methodology.[14] In the GRADE assessment process, 
the quality of a body of evidence is defined as the 
extent to which one can be confident that the reported 
estimates of effect (desirable or undesirable) available 
Evidence level Rationale
High Further research is very unlikely to change our confidence in the 
estimate of effect.
Moderate Further research is likely to have an important impact on our 
confidence in the effect.
Very low 
Low 
Any estimate of effect is very uncertain.
Further research is very likely to have an estimate of effect and is 
likely to change the estimate.
from the evidence are close to the actual effects of 
interest. The usefulness of an estimate of the effect (of 
the intervention) depends on the level of confidence in 
that estimate. The higher the quality of evidence, the 
more likely a strong recommendation can be made; 
however, the decision regarding the strength of the 
evidence also depends on other factors. Although 
the GRADE evidence assessment process was used 
for all of the questions, it was not always possible 
to calculate GRADE profiles for all the questions 
because there was a lack of data and information to 
calculate the necessary risk ratios. The initial ranking 
of the evidence for each question was collectively 
done by the consultants of the systematic review and 
members of the WHO Steering Group, which was later 
presented and discussed by the Guidelines Group. 
In the GRADE profiles, the following levels of 
assessment of the evidence were used: 
Reports were also commissioned from people living 
with HIV and affected communities regarding the key 
questions and the summary of the evidence (Annex 4). 
The final recommendations also take into consideration 
the quality of the evidence, cost, feasibility, and values 
and preferences of the community, and health-care 
workers. The Guidelines Group, which included two 
GRADE methodologists, assessed the evidence along 
with the risks and benefits of each recommendation, 
and determined their recommendations and the 
strength of the evidence. The Group used open voting 
and discussion to arrive at a consensus for each of the 
recommendations. After the initial draft was reviewed 
by the Guidelines Group, the comments were 
incorporated into a draft that was then sent to over 
200 people for peer review. The Coordinators of the 
process, representing the two technical units of WHO 
(HIV/AIDS and Stop TB Departments), incorporated 
comments from around 30 internal and external peer 
reviewers to finalize the recommendations.
1.5 Strength of recommendations 
The strength of the recommendations reflects the degree of confidence of the Guidelines Group that the desirable effects of adherence to the 
recommendations outweigh the undesirable effects. 
Desirable effects considered include beneficial health 
outcomes (e.g. prevention and early diagnosis of TB, 
reduced TB-related morbidity and mortality), less 
burden and savings, whereas undesirable effects 
can include harms, more burden and costs. Burdens 
considered include the demands of adhering to 
the recommendations that programmes, patients 
or caregivers (e.g. family) may have to bear, such 
as having to undergo more frequent tests, taking 
additional medications or opting for a treatment that 
has a risk for toxicity. 
The recommendations in these guidelines were 
graded into two categories as follows:
A STRONG RECOMMENDATION is one for which 
the Guidelines Group is confident that the desirable 
effects of adherence to the recommendation 
outweigh the undesirable effects. This can be either 
in favour of or against an intervention.
A CONDITIONAL (WEAK) RECOMMENDATION is 
one for which the panel concludes that the desirable 
effects of adherence to the recommendation probably 
outweigh the undesirable effects, but the panel is 
not confident about these trade-offs. Reasons for 
not being confident can include: absence of high-
quality evidence, presence of imprecise estimates of 
benefits or harms, uncertainty or variation regarding 
how different individuals value the outcomes, 
small benefits, and benefits that may not be worth 
the costs (including the costs of implementing the 
recommendation).  
Background and process
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1.6 Adaptation of the guidelines
The guidelines have been developed for a global audience and it is expected that regions and countries will adapt the recommendations 
to suit their own circumstances. These include 
consideration of the epidemiology of TB and HIV, 
and defining settings with the highest rates of 
prevalence and transmission of TB among people 
living with HIV (for example, to implement IPT 
lifelong or for 36 months). The ultimate goal of these 
adaptations should be to scale up implementation of 
services for TB screening, prevention and treatment 
as core functions of HIV prevention, treatment and 
care services. Depending on the situation of the 
country, a national consultation process involving 
all the stakeholders should help ensure the creation 
of a policy and programme environment that is 
conducive to implementation. Critical factors that 
need to be addressed during the national adaptation 
process include incorporation of TB screening and 
IPT as core interventions in the treatment and care 
package for people living with HIV. Other critical 
functions include the development of standardized 
operating procedures, access to INH (preferably 
300 mg tablets) for HIV service providers and 
implementers, and establishment of an effective 
and standardized monitoring and evaluation 
(M&E) system. The evaluation of the efficacy of 
the guidelines will be done through the global TB 
and HIV/AIDS reporting system, which will monitor 
country and global implementation of IPT and ICF. 
In addition, WHO and ministries of health, along 
with key stakeholders, will participate in country-
level programme reviews to monitor adaptation and 
implementation of the guidelines. Feedback from 
the community and other stakeholders will be used 
to revise the next edition of the guidelines.
Strength of recommendation Rationale
Strong
Conditional (weak)
The panel is confident that the desirable effects of adherence to the 
recommendation outweigh the undesirable effects.
The panel concludes that the desirable effects of adherence to the 
recommendation probably outweigh the undesirable effects.
However:
• Data to support the recommendation are scant; or
• The recommendation is only applicable to a specific group, 
population or setting; or
• New evidence may result in changing the balance of risk to 
benefit; or
• The benefits may not warrant the cost or resource requirements 
in all settings.
2. Intensified case-finding for and prevention of 
tuberculosis in adults and adolescents living 
with HIV
2.1 Screening for TB
Adults and adolescents living with HIV should be screened for TB with a 
clinical algorithm and those who do not report any one of the symptoms 
of current cough, fever, weight loss or night sweats are unlikely to have 
active TB and should be offered IPT. 
Adults and adolescents living with HIV and screened for TB with a 
clinical algorithm and who report any one of the symptoms of current 
cough, fever, weight loss or night sweats may have active TB and 
should be evaluated for TB and other diseases.
Strong recommendation, moderate quality of evidence
Strong recommendation, moderate quality of evidence
All people living with HIV, wherever they receive 
care, should be regularly screened for TB using a 
clinical algorithm at every visit to a health facility or 
contact with a health worker. Screening for TB is 
important, regardless of whether they have received 
or are receiving IPT or ART. As part of the guidelines 
development process, a comprehensive systematic 
primary patient data meta-analysis, including 12 
observational studies involving over 8000 people 
living with HIV, was used to develop the best 
screening rule to identify adults and adolescents 
living with HIV who are unlikely to have active TB 
disease (Annex 5).[15] The analysis found that the 
absence of all the symptoms of current cough, night 
sweats, fever or weight loss can identify a subset of 
people living with HIV who have a very low probability 
of having TB disease. This best screening rule has 
a sensitivity of 79% and a specificity of 50%. At 
5% TB prevalence among people living with HIV, 
the negative predictive value was 97.7% (95%CI 
97.4–98.0). This high negative predictive value 
ensures that those who are negative on screening 
are unlikely to have TB and hence can reliably start 
IPT. Therefore, the Guidelines Group recommends 
that adults and adolescents living with HIV should be 
screened for TB using a clinical algorithm at every 
visit to a health facility or contact with a health worker. 
Those who do not have current cough, fever, weight 
loss or night sweats are unlikely to have active TB 
and should be offered IPT. This recommendation is 
applicable for those living with HIV irrespective of the 
degree of immunosuppression, and for those on ART, 
those who have previously been treated for TB and 
pregnant women (Figure 1).  
Furthermore, the GRADE assessment of the evidence 
showed that the addition of abnormal findings on chest 
radiography to the four-symptom-based rule increases 
the sensitivity from 79% to 91% with a drop in specificity 
from 50% to 39%. At a 5% TB prevalence rate among 
people living with HIV, augmenting the symptom-based 
rule with abnormal findings on chest radiography 
increases the negative predictive value by a margin of 
only 1% (98.7% versus 97.8%). On the other hand, the 
addition of abnormal chest radiographic findings to the 
symptom-based rule at a TB prevalence of 20% among 
people living with HIV increases the negative predictive 
value by almost 4% (94.3% versus 90.4%). This 
suggests that chest radiography could be considered 
to augment the utility of symptom-based screening 
in settings with high TB prevalence rates among 
people living with HIV. However, the Guidelines Group 
recognized that the desire for increased sensitivity 
and negative predictive value is often accompanied by 
significant feasibility concerns such as cost, workload, 
infrastructure and qualified staff. Therefore, the 
Guidelines Group recommends that in most settings, 
the symptom-based rule should be implemented, 
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2.2.2 Regimen and duration
2.2 Efficacy, regimen and duration
Adults and adolescents living with HIV who have an unknown or positive 
TST status and who are unlikely to have active TB should receive at 
least six months of IPT as part of a comprehensive package of HIV 
care. IPT should be given to such individuals irrespective of the degree 
of immunosuppression, and also to those on ART, those who have 
previously been treated for TB and pregnant women.
Adults and adolescents living with HIV who have an unknown or positive 
TST status and are unlikely to have active TB should receive at least 36 
months of IPT. IPT should be given to such individuals irrespective of the 
degree of immunosuppression, and also to those on ART, those who have 
previously been treated for TB and pregnant women.
Strong recommendation, high quality of evidence
Conditional recommendation, moderate quality of evidence
2.2.1 Efficacy
The Guidelines Group reviewed the available evidence regarding the benefit of chemotherapy preventing TB disease (latent disease, 
reactivation or reinfection) in adults living with HIV 
(Annex 6). A GRADE assessment was used to 
examine the existing evidence on drug regimens 
including the 12 randomized controlled trials used in 
the Cochrane review of preventive therapy.[16] For 
those with confirmed, probable or possible TB disease, 
preventive chemotherapy reduces the overall risk of 
developing TB by 33% (relative effect 0.67; CI 0.51–
0.87). For those who were TST positive, the reduction 
in confirmed, probable or possible TB increased to 
64% (RR [95% CI] 0.36 [0.22–0.61]). Although not 
statistically significant, the reduction among TST-
negative persons was 14% (RR [95% CI] 0.86 [0.59, 
1.26]) and in those with unknown TST status it fell by 
14% (RR [95% CI] 0.86 [0.48, 1.52]).[16] The Guidelines 
Group concluded that there is benefit in providing TB 
preventive therapy to people living with HIV regardless 
of the TST status, with greater protective benefit seen 
in those with a positive TST.   
The Guidelines Group reviewed the evidence on a wide range of regimens used for TB prevention and their duration among people living with HIV, 
including results from three unpublished trials (Annex 6). 
The Group reviewed studies of the drug combinations 
used for prevention including INH, rifampicin, 
pyrazinamide and rifapentine. A total of eight studies 
compared INH alone with other regimens, and found 
that regimens that included pyrazinamide, rifampicin 
and rifapentine were as efficacious as INH alone, but 
were associated with higher rates of toxicity (Table 1). 
The Guidelines Group concluded that INH at 300 mg/
day remains the drug of choice for chemotherapy to 
prevent TB in adults living with HIV. 
The Guidelines Group also reviewed the evidence on 
the duration and durability of effect of IPT in people 
living with HIV. The critical outcomes of interest 
considered were the efficacy of IPT in preventing active 
TB, relapse, reinfection and toxicity. 
regardless of the availability of radiography, consistent 
with the recommended algorithm (Figure 1). 
Adults and adolescents living with HIV who have any 
one of the four symptoms (current cough, fever, weight 
loss or night sweats) may have active TB and should 
be evaluated for TB and other diseases. The diagnostic 
work-up for TB should be done in accordance with 
national guidelines and sound clinical practice to 
identify either active TB or an alternative diagnosis.
Intervention   Comparator RR (95% CI)   Quality of evidence
INH      
INH      
INH      
INH and rifampicin   
INH and rifapentine   
Rifampicin and  pyrazinamide
INH and  rifampicin
INH, rifampicin and pyrazinamide 
INH, rifampicin and pyrazinamide 
INH
1.03 (0.75–1.4)
0.97 (0.52–1.83)
0.69 (0.23–1.57)  
0.75 (0.21–1.82)
1.05 (0.56–1.97)  
Moderate
Moderate
Low
Moderate
Moderate
2.2.2.1 Table 1: Comparison of the efficacy of different drug regimens 
The Guidelines Group considered the existing 
evidence on the optimal duration of IPT including for 
six, nine, 12 and 36 months (Annex 6). The evidence 
primarily focused on the comparison of a six- and 
12-month duration of IPT, and found no significant 
difference in efficacy.[16] Although nine months of 
IPT is supported by evidence and recommended 
in some guidelines, there are no studies that have 
directly compared IPT for six and nine months. This 
led the Guidelines Group to strongly recommend 
the six-month duration. The protective effect of IPT 
decreases with time and the durability ranges for 
up to five years. The Guidelines Group reviewed 
emerging unpublished evidence from two clinical 
trials that suggest increased benefit with a 36-month 
or longer duration of IPT, particularly in people who 
are TST positive.[17,18] Given that longer trials are 
expensive and unlikely to be done, the Guidelines 
Group considered a duration of at least 36 months as 
a surrogate for lifelong treatment. It also emphasized 
the potential benefit of extended IPT for people 
living with HIV in settings with a background of high 
HIV and TB prevalence and transmission. Given 
the preliminary and scanty nature of the evidence, 
feasibility concerns and potential adverse events, 
the Guidelines Group conditionally recommends 36 
months’ duration of IPT for people living with HIV in 
settings with high TB prevalence and transmission, 
as determined by the local context and national 
guidelines.  
2.2.3 Immune status and concomitant use of IPT with ART
The Guidelines Group reviewed available data regarding the initiation of IPT and immune status, including concomitant use with 
ART. Six studies were examined which showed 
contrasting results regarding the reduction of TB risk 
by immune status (Annex 6). Additional protective 
benefits of concomitant use of IPT with ART were 
demonstrated in two observational studies from 
Brazil [19] and South Africa,[20] and a sub-analysis 
of data from an unpublished randomized clinical trial 
from Botswana.[17] Based on this evidence and the 
potential benefit of concomitant use of IPT with ART, 
the Guidelines Group strongly recommends that IPT 
be given irrespective of immune status and whether 
or not a person is on ART. IPT initiation or completion 
should not be the cause for a delay in starting ART 
for eligible people living with HIV.[21] However, 
the Guidelines Group recognizes the absence 
of evidence on whether concomitant initiation of 
IPT with ART or delayed initiation of IPT is better 
in terms of efficacy, toxicity or the development of 
immune reconstitution.
2.2.4 Pregnant women 
Pregnant women living with HIV are at risk for TB, which can impact on maternal and perinatal outcomes.[22] These could range 
from death of the mother and the newborn, to 
prematurity and low birth weight of the newborn.
[23] The Guidelines Group stressed the importance 
of screening pregnant women living with HIV for 
active TB using the clinical algorithm as mentioned 
above. This implies the introduction of the clinical 
algorithm into maternal HIV services in order 
to prevent, diagnose and treat TB. The Group 
concluded that evidence and experience from the 
pre-HIV and HIV era suggest that IPT is safe in 
pregnant women. Therefore, the Guidelines Group 
strongly recommends that pregnancy should not 
exclude women living with HIV from symptom-
based TB screening and receiving IPT. However, 
sound clinical judgement is required for decisions 
such as the best time to provide IPT to pregnant 
women.
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2.2.6 Special populations
People living with HIV in congregate settings, such as prisons and centres for refugees or internally displaced persons, have a higher risk 
for and incidence of TB, HIV infection and drug use.[2] 
Special attention has to be paid to ensure screening 
for TB and provision of IPT for these groups. Injecting 
drug users have a higher risk of coinfections with 
HIV, TB and hepatitis-causing viruses. Screening 
for TB and providing IPT for injecting drug users 
should be combined with harm reduction measures, 
including the provision of testing for hepatitis B and 
hepatitis C infection, and referral for positive cases.
[28] Sound clinical judgement is required to weigh 
the benefits of IPT among injecting drug users with 
hepatitis coinfection. IPT should not be provided in 
the presence of active hepatitis.
2.2.7 Figure 1.  Algorithm for TB screening in adults and adolescents 
living with HIV in HIV-prevalent and resource-constrained settings
FOOTNOTES TO ALGORITHM FOR ADULTS
* Every adult and adolescent should be evaluated for eligibility to receive ART. Infection control measures should be prioritized to 
reduce M. tuberculosis transmission in all settings that provide care.
Ɨ Chest radiography can be done if available, but is not required to classify patients into TB and non-TB groups. In high HIV-
prevalence settings with a high TB prevalence among people living with HIV (e.g. greater than 10%), strong consideration must be 
given to adding other sensitive investigations.
ǂ Contraindications include: active hepatitis (acute or chronic), regular and heavy alcohol consumption, and symptoms of peripheral 
neuropathy. Past history of TB and current pregnancy should not be contraindications for starting IPT.  Although not a requirement for 
initiating IPT, TST may be done as a part of eligibility screening in some settings. 
§ Investigations for TB should be done in accordance with existing national guidelines.
Adults and adolescents living with HIV*
Screen for TB with any one of the following symptomsƗ:
Current cough
Fever
Weight loss
Night sweats
Assess for contraindications to IPTǂ
Screen for TB regularly at each encounter with a health worker or visit to a health facility
No
Give IPT Defer IPT
Yes
Investigate for TB and other diseases§
Not TB
Follow up 
and 
consider IPT
Treat 
for 
TB
Other diagnosis
Give appropriate 
treatment and 
consider IPT
TB
No Yes
2.2.5 Patients previously treated for TB (secondary prophylaxis)
The Guidelines Group reviewed the evidence and discussed IPT as secondary prophylaxis for people who have previously been 
successfully treated for TB. GRADE assessment 
of the evidence from four studies including three 
randomized controlled trials [24–26] and one 
observational study [27] showed the value of providing 
IPT immediately after successful completion of 
TB treatment (Annex 7). The Guidelines Group 
strongly recommends that adults and adolescents 
living with HIV who successfully complete their TB 
treatment should continue receiving INH for another 
six months and should conditionally receive it for 36 
months based on the local situation (e.g. high rates 
of TB prevalence and transmission) and existing 
national guidelines. There was no evidence on the 
potential role of IPT for those who had successfully 
completed treatment for multidrug-resistant 
(MDR) or extensively drug-resistant (XDR) TB. 
Therefore, the Guidelines Group did not make any 
recommendation on the use of IPT after successful 
treatment for MDR or XDR TB. 
2.3 Detecting latent TB infection in resource-constrained settings
2.3.1 Tuberculin skin test (TST) and IPT
TST is not a requirement for initiating IPT in people living with HIV.
People living with HIV who have a positive TST benefit more from IPT; 
TST can be used where feasible to identify such individuals.
Strong recommendation, moderate quality of evidence
Strong recommendation, high quality of evidence
TST relies on a competent immune response 
to identify people with latent Mycobacterium 
tuberculosis infection. Multiple studies in people 
living with HIV demonstrate that IPT is more effective 
in people with a positive TST than in those with a 
negative test.[16] In addition, the use of TST could 
reduce the number of patients receiving IPT and the 
numbers needed to treat to prevent one case of active 
TB. However, in resource-constrained settings, 
operational challenges to the implementation of TST 
are significant impediments for access to IPT. Such 
challenges include the costs of procuring tuberculin 
and administering the test, maintaining an effective 
supply chain, training staff in administering and 
accurately reading the test, and the need for the 
patient to attend the clinic at least twice over 48–72 
hours with its associated inconvenience and cost.[29] 
In addition, the immunological status of the patient 
and the negative results in anergic patients or those 
with a long lapse between infection and the TST 
may affect its interpretation.[30,31] Although some 
studies suggest that using TST is cost-effective, 
there is a limited supply of tuberculin worldwide, it is 
costly to ship and requires an adequate cold chain 
to ensure accurate test performance (see Annex 8). 
The Guidelines Group strongly recommends that 
in resource-constrained settings, TST should 
not be a requirement for initiating IPT for people 
living with HIV. People living with HIV whose TST 
status is unknown should be started on IPT after 
symptom-based screening for TB. However, given 
that TST-positive patients benefit more from IPT 
than those who are TST negative, the test can be 
used where feasible. People living with HIV who are 
TST negative should be assessed on a case-by-
case basis for their individual risk of TB exposure 
and the added advantage of the provision of IPT 
(e.g. health-care workers, prisoners, miners and 
others who live in a high TB transmission setting). In 
settings where TST is not available, the Guidelines 
Group encourages national programmes to explore 
its expanded use as a potential adjunct to enhancing 
IPT implementation.  
2.3.2 Interferon-gamma release assays (IGRA)
The Guidelines Group discussed the GRADE assessment of the evidence on the use of IGRA as a screening tool to identify patients 
with latent TB infection (Annex 9). Two types of IGRA 
were considered: Quantiferon Gold in tube assay 
and T-Spot assay. Two studies considered the ability 
of IGRA to predict development of TB over time.
[32,33] Eight studies evaluated the performance of 
Quantiferon Gold in tube assay among HIV-infected 
adults with confirmed TB, and one study evaluated its 
sensitivity among children living with HIV diagnosed 
with TB. Similarly, five studies reported the sensitivity 
of a T-Spot assay among adults living with HIV and 
TB, and two studies reported its sensitivity among 
children living with HIV with confirmed TB. 
However, IGRA cannot generally distinguish 
between active TB disease and latent infection 
[34] and their performance is compromised among 
people living with HIV compared to those without 
HIV. Significantly higher rates of indeterminate 
test results were found with Quantiferon Gold in 
tube test in persons with HIV compared to persons 
without HIV, and in persons with low CD4 cell counts 
compared to persons with higher CD4 cell counts. 
Its sensitivity was also markedly reduced among 
patients with low CD4 counts. Similarly, while most 
studies found no impact of low CD4 cell count on the 
sensitivity of T-Spot assay, at least one study found 
that sensitivity was significantly reduced among 
patients with low CD4 counts. 
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HIV treatment and care services should include a comprehensive approach to preventing, diagnosing and treating TB 
with an emphasis on the Three I’s for HIV/TB. The 
Guidelines Group concluded that providing IPT as 
a core component of HIV preventive care should be 
the responsibility of national AIDS programmes and 
HIV service providers. In addition, IPT should not 
be viewed as an isolated intervention and should be 
part of a TB prevention package along with infection 
control for TB, ICF and the provision of early ART 
to those with CD4 counts <350 cells/mm3 (people 
with TB should receive ART irrespective of CD4 
count). National AIDS programmes and providers 
of HIV services should ensure the meaningful 
engagement of people living with HIV, persons with 
TB and their communities in both the planning and 
implementation of these interventions.[35]
The implementation of TB screening and IPT needs 
to be monitored and evaluated through established 
and recommended patient M&E systems [36] that 
should use internationally recommended indicators.
[37] HIV stakeholders implementing TB screening 
and IPT in resource-limited settings outside of the 
facilities run by the government should ensure that 
a reporting mechanism is established so that  their 
data are captured in one national M&E system. 
2.4 Issues to consider for implementation of IPT
2.4.1 Primary ownership by HIV service providers
2.4.2 IPT and drug-resistant TB
Providing IPT to people living with HIV does not increase the risk 
of developing INH-resistant TB. Therefore, concerns regarding the 
development of INH resistance should not be a barrier to providing IPT.
Strong recommendation, moderate quality of evidence
One of the reasons commonly cited for not offering 
IPT to people living with HIV is the fear of developing 
drug-resistant TB. The Guidelines Group reviewed the 
evidence on the provision of IPT and drug-resistant 
TB, which was presented after GRADE assessment of 
the evidence (Annex 10). This included eight studies 
and the results of a meta-analysis which concluded 
that INH resistance is not significantly associated with 
the provision of IPT.[38] The GRADE assessment of 
the evidence examined the relative risk of developing 
INH-resistant TB among all of those receiving isoniazid 
and found no statistically significant increased risk of 
resistance (RR 95% CI= 1.87 [0.65–5.38]). In addition, 
the results of a study that was under publication and 
showed no risk of development of drug resistance 
after provision of IPT to gold miners were also 
presented and discussed.[39] The Guidelines Group 
also noted that regular TB screening for those taking 
IPT will help identify those who could develop TB as 
early as possible. This early identification will allow for 
prompt diagnosis and treatment, which should also 
help to prevent the development of drug-resistant TB. 
The Guidelines Group noted that in settings with high 
INH resistance, fewer patients are likely to benefit 
from IPT, and the decision to provide access to IPT 
for people living with HIV should thus be based on 
the local context. Programmes implementing IPT are 
encouraged to introduce international and national TB 
drug-resistance surveillance systems that also include 
HIV testing as an integral component.
2.4.3 Adherence and clinical follow up
The Guidelines Group reviewed the evidence regarding the importance of adherence to IPT (Annex 11). The available data were observational and did not directly address whether poor adherence adversely affects individual or programme outcomes. Adherence rates for IPT 
The Guidelines Group noted that the data suggesting 
the use of IGRA to identify latent TB in persons living 
with HIV are restricted to studies conducted in low 
TB-prevalence settings and there is no evidence that 
IGRA will determine who will benefit most from IPT. 
Based on the available data, the Guidelines Group 
concluded that IGRA are not recommended to screen 
people living with HIV for eligibility to receive IPT.
2.4.4 Cost-effectiveness of IPT
The Guidelines Group concluded that the available data on the cost-effectiveness of IPT is of low quality with significant variability between 
outcome measures, assumptions and analytical 
procedures (Annex 12). It was recognized that this 
is an area that requires additional research to better 
inform programmatic decision-making. However, 
after a review of the evidence, the Guidelines Group 
strongly recommends that the provision of IPT is 
likely to be cost-effective. This supports the overall 
recommendation for the wide use of IPT within 
comprehensive HIV prevention, care and treatment 
services, both as a measure of good clinical practice 
and as a likely cost-effective measure. 
varied widely from 34% to 98%, and a number of 
factors were identified to improve adherence.[40–
44]  
 The Guidelines Group noted that, although treatment completion is important for good 
individual and programme outcomes, the primary 
objective should be to ensure that people do not 
continue to take IPT in the rare instance of active 
TB or development of toxicity. People living with 
HIV and receiving IPT should have regular clinical 
follow up based on the national, local and clinical 
context. This includes regular screening using 
the TB symptom-based rule during every contact 
with a health-care provider. The Guidelines Group 
noted that the co-formulation of INH with other 
drugs (e.g. ART or CPT) could reduce the pill 
burden and enhance adherence, and called for 
expedited development of such co-formulations. 
The Guidelines Group strongly recommends that 
concerns regarding adherence should not be a 
barrier to implementing IPT.
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3. Intensified tuberculosis case-finding 
and prevention of tuberculosis in children 
living with HIV
3.1 Screening for TB
Children living with HIV who do not have poor weight gain,* fever or 
current cough are unlikely to have active TB. 
Children living with HIV who have any one of the following 
symptoms – poor weight gain*, fever, current cough or contact history 
with a TB case – may have TB and should be evaluated for TB and 
other conditions. If the evaluation shows no TB, they should be offered 
IPT regardless of their age.
* Poor weight gain is defined as reported weight loss, or very low weight (weight-for-age less 
than –3 z-score), or underweight (weight-for-age less than –2 z-score), or confirmed weight 
loss (>5%) since the last visit, or growth curve flattening.
Strong recommendations, low quality of evidence
Encouraging efforts have been made to expand 
access to early diagnosis of HIV in children as part 
of HIV prevention, care and treatment. TB screening, 
prevention and treatment should be an integral part 
of these services. This section of the guidelines 
is specifically targeted at children living with HIV. 
However, in circumstances where HIV-exposed 
infants and children are receiving HIV care pending 
a result of a virological or serological test, they should 
be considered as children living with HIV and get the 
appropriate services until their results are known. 
For infants less than 6 weeks of age and unknown 
HIV exposure, and in settings where the HIV epidemic 
is generalized (i.e. >1% prevalence in the population 
attending antenatal care services), programmes are 
strongly recommended to provide HIV serological 
testing to mothers or their infants in order to establish 
exposure status. Virological testing should be 
conducted at 4–6 weeks of age for infants known to be 
exposed to HIV, or at the earliest possible opportunity 
for those seen after 4–6 weeks of birth. For children 12–
18 months of age, diagnosis using virological testing 
is recommended. However, in resource-constrained 
settings where access to virological testing is limited, 
it is recommended that, for this age group, virological 
tests be performed only after positive serological 
testing. A definitive diagnosis of HIV in children aged 
18 months or more (with known or unknown HIV 
exposure) can be made with HIV serological tests, 
including rapid serological tests following standard 
testing algorithms used for adults.[45]
The Guidelines Group stressed that infants and 
children living with HIV should routinely be screened 
for TB as a part of standard clinical care, whether 
they are receiving TB prophylaxis or ART. However, 
the diagnosis of TB in children, with or without HIV, is 
difficult and clinicians need a high index of suspicion 
at all times and should follow national guidelines. A 
history of contact of the infant or child with someone 
with TB (regardless of the type of TB disease) within 
the home is particularly important and should motivate 
the health-care worker to screen for TB in the child 
and among the other family members. 
Based on this analysis and the relative lack of good 
studies, the Guidelines Group concluded that the 
quality of evidence is low and available data are 
limited regarding the best approach to screening 
infants and children for TB. The range of evidence 
assessed using GRADE included a number of scoring 
systems for children who are not infected with HIV. 
However, such scoring systems were not found to be 
as effective in children living with HIV (Annex 13).[46] 
The evidence also included one unpublished study 
that investigated a combination of signs and symptoms 
to reliably exclude active TB in a child with HIV. The 
study showed that the absence of cough of more 
than two weeks’ duration, fever and failure to thrive 
could identify children unlikely to have active TB with 
a 99% negative predictive value. Such children would 
therefore be eligible for IPT. Similarly, the presence of 
cough for more than two weeks, or failure to thrive or 
fever has a sensitivity of 90% and specificity of 65%, 
and is therefore useful for identifying children in need 
of further screening for TB or alternative diagnoses.
[47] Another study among 1024 children suggested 
that weight loss and cough for more than two weeks 
and fatigue had a sensitivity of only 56% and specificity 
of 62%.[48] 
In order to facilitate programmatic implementation and 
increase the likelihood of identifying children without 
active TB for IPT, the Guidelines Group recommends 
that the duration of cough as a screening rule should 
be reduced to the presence of any current cough, 
in line with the recommendation for adolescents 
and adults. Unlike the screening rule for adults and 
adolescents, this recommendation is based on expert 
opinion and clinicians need to broaden the differential 
diagnosis to include other diseases that may cause 
children with HIV to present with current cough, fever 
and poor weight gain. Similarly, contact history with a 
known TB case should raise the clinical suspicion of 
TB in children living with HIV. 
The Guidelines Group recommends that children 
living with HIV without poor weight gain, fever and 
current cough are unlikely to have active TB and 
should be offered IPT (see below for age-specific 
recommendations). Similarly, children living with HIV 
with any one of the following symptoms – poor weight 
gain, fever, current cough and contact with a TB case 
– may have TB and should be evaluated for TB and 
other diseases. If the evaluation shows no TB, such 
children should be offered IPT regardless of their age 
(Figure 2).     
3.2 Regimen and duration
Children living with HIV who are more than 12 months of age and who 
are unlikely to have active TB on symptom-based screening, and have 
no contact with a TB case should receive six months of IPT (10 mg/kg/
day) as part of a comprehensive package of HIV prevention and care 
services.
In children living with HIV who are less than 12 months of age, only 
those who have contact with a TB case and who are evaluated for TB 
(using investigations) should receive six months of IPT if the evaluation 
shows no TB disease.
All children living with HIV who have successfully completed treatment 
for TB disease should receive INH for an additional six months.
Strong recommendations, moderate quality of evidence
Conditional recommendation, low quality of evidence
Two studies were considered for the GRADE 
assessment of the evidence (Annex 14). One 
study suggested considerable benefits for children 
receiving INH for six months, in particular, with 
regard to significant reductions in mortality.[49] 
However, findings from a randomized control 
trial conducted in South Africa showed that when 
HIV-infected infants with no known exposure to a 
TB source case are identified in the first three to 
four months of life, given rapid access to ART and 
carefully monitored for new TB exposure or disease 
on a monthly basis, there is no benefit from IPT 
(Madhi 2008, unpublished). 
Therefore, based on this, the Guidelines Group 
recommends that all children living with HIV who are 
more than 12 months of age and who are unlikely to 
have active TB should receive six months of IPT as 
part of a comprehensive package of HIV care. For 
children less than 12 months of age, only those who 
have been evaluated for TB (using investigations) 
should receive six months IPT if the evaluation 
shows no TB disease. In contrast to adults and 
adolescents, there is no evidence to support the 
use of INH for longer than six months in children. 
Therefore, the Guidelines Group concluded that until 
more data are available, INH for children could not 
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Weight range (kg) Number of 100 mg tablets of INH to be 
administered per dose (total dose 10 mg/kg/day)
Dose given (mg)
 tablet
1 tablet
1  tablet 
2 tablets
2  tablets
3 tablets or one adult tablet 
<5
5.1–9.9
10–13.9
14–19.9
20–24.9
>25
 50 
100
150
200
250
300
3.3 Secondary prophylaxis and IPT with ART in children
3.3.1 Secondary prophylaxis 
3.3.2 IPT with ART in children
3.4 The role of TST and IGRA in evaluating children for IPT
The Guidelines Group noted that there is no evidence on the use of IPT in children living with HIV after successful completion of TB 
treatment. However, like adults, children living 
with HIV are exposed to reinfection and recurrence 
of TB. Therefore, the Group conditionally 
recommends that all children living with HIV who 
have been successfully treated for TB and are 
living in settings with a high TB prevalence and 
transmission should receive IPT for an additional 
six months. IPT can be started immediately after 
the last dose of anti-TB therapy or at a later 
date. TB screening should be carried out for all 
children living with HIV, regardless of history of TB 
treatment, during each contact of the child with a 
health-care worker (Annex 13). 
The Guidelines Group concluded that there are no data regarding the efficacy of IPT for children stratified by degree of immunosuppression. 
However, it was noted that there is biological 
plausibility in extrapolating what is known for adults 
and adolescents to children. Therefore, the Guidelines 
Group conditionally recommends the combined use of 
IPT with ART for all children. The Guidelines Group 
also emphasized that ART should not be delayed 
while starting or completing a course of IPT.[45]
The Guidelines Group, as in the recommendation for adults, concluded that TST is not required to initiate IPT in children and should not be 
routinely used as part of the process to determine 
eligibility for IPT (Annex 9). However, the Group 
noted that TST may provide important additional 
information in assessing a child with suspected 
TB, especially if there is no positive contact history. 
Although a positive TST may indicate infection with 
mycobacteria, usually Mycobacterium tuberculosis, it 
is not a reliable marker of TB disease activity. The 
main limitation of TST in the diagnosis of TB in HIV-
infected children is its variable sensitivity. Important 
clinical causes of false-negative results include 
severe malnutrition, severe TB disease and HIV 
infection. Therefore, in settings where it is available, 
TST may be used for the diagnosis of active TB in 
children and may also have a role in screening for 
LTBI. 
Like TST, IGRA cannot distinguish between M. 
tuberculosis infection and active TB disease. 
be recommended for more than six months. Similarly, 
there is no evidence on whether repeating a course 
of IPT is beneficial for children.
INH should be given at a dose of 10 mg/kg body 
weight and it is desirable that vitamin B6 be supplied 
with INH at a dose of 25 mg daily. All available data 
to date suggest that INH is not toxic for children, even 
in those receiving ART. The following table shows a 
simplified dosing schedule for children (total dose 10 
mg of INH/kg/day).
No Yes
FOOTNOTES TO ALGORITHM FOR CHILDREN 
* All children and infants less than one year of age should be provided with IPT if they have a history of household contact with a TB 
case.  
Ɨ Poor weight gain is defined as reported weight loss, or very low weight (weight-for-age less than –3 z-score), or underweight (weight-
for-age less than –2 z-score), or confirmed weight loss (>5%) since the last visit, or growth curve flattening.
ǂ Contraindications include: active hepatitis (acute or chronic) and symptoms of peripheral neuropathy. Past history of TB should not 
be a contraindication for starting IPT. Although not a requirement for initiating IPT, TST may be done as a part of eligibility screening 
in some settings. 
§ Investigations for TB must be done in accordance with existing national guidelines.
3.5 Figure 2: Algorithm for TB screening in children more 
than one year of age and living with HIV
Child more than 12 months of age and living with HIV*
Screen for TB with any one of the following symptoms:
Poor weight gainƗ
Fever
Current cough
Contact history with a TB case
Assess for contraindications to IPTǂ
Screen regularly for TB 
No
Give IPT Defer IPT
Yes
Investigate for TB and other diseases§
Not TB
Follow up 
and 
consider IPT
Treat 
for TB
Other diagnosis
Give 
appropriate 
treatment and 
consider IPT
TB
Encouraging data show that IGRA are more sensitive 
than TST in HIV-infected children, including those 
with a low CD4 count and/or malnutrition.[50–52]. 
In addition, excellent specificity for M. tuberculosis 
infection has been reported and, unlike TST, IGRA 
are unaffected by prior BCG vaccination or exposure 
to environmental mycobacteria. However, more 
evidence is needed and implementation issues 
affecting most HIV-prevalence settings (cost, specific 
laboratory equipment and the need for a venous 
blood sample) have to be addressed. Therefore, 
the Guidelines Group strongly recommends that 
there is currently insufficient evidence to support 
the use of IGRA to identify children eligible for IPT 
outside research settings with laboratory-validated 
procedures.[53]
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The review of the evidence for formulating the recommendations exposed important unmet research needs (Annex 15). The Guidelines 
Group discussed the priority research gaps that 
need to be addressed in order to update these 
guidelines. The following are the key questions 
identified by the Guidelines Group in all the areas 
included in these guidelines. It is imperative that 
research, donors and the scientific community 
expedite the implementation of research to respond 
to these gaps in order to inform policy formulation 
and programme implementation. Along with global 
TB and HIV stakeholders, WHO has developed a 
document that summarizes the overall research 
priorities around TB/HIV and addresses the broader 
context of research gaps.[54]
4. Research gaps
4.1 Screening for TB
4.2 Preventive treatment for TB
• A new point-of-care test is needed to identify 
those with active TB, LTBI and those not infected 
with M. tuberculosis; particular emphasis should 
be placed on new diagnostics for children.
• The role of IGRA in people living with HIV who 
are infected with M. tuberculosis with or without 
active TB; information is needed about the 
association between performance of IGRA and 
immune status.
• The use of TST testing in people living with HIV 
and receiving ART, with a particular emphasis on 
the frequency of performing TST to determine 
immune reconstitution and/or boosting in those 
who were initially TST negative.
• The optimal TB screening algorithm to be used 
across different settings with different TB and 
HIV disease burdens to safely initiate preventive 
therapy 
• The optimal frequency of screening people 
with HIV for active TB with a symptom-based 
questionnaire
• Evaluation of the WHO-recommended algorithm 
to diagnose TB using new technological advances 
such as LED microscopy, rapid culture and 
polymerase chain reaction (PCR)-based methods
• Further validation of the screening algorithm in 
various programmatic settings
• Effect of ICF on nosocomial transmission, in 
particular, among people living with HIV, health-
care workers and/or their families
• Optimal diagnostic algorithm for diagnosis of TB 
following TB screening for IPT.
• Optimal duration, safety, efficacy and cost-
effectiveness of IPT alone or in conjunction with 
ART in reducing the risk of active TB, compared 
to ART alone among people living with HIV, 
particularly under programme conditions
• Co-formulation as a fixed-dose combination of 
isoniazid and vitamin B6 with co-trimoxazole, 
and with antiretrovirals, and evaluation of the 
efficacy and effectiveness of such fixed-dose 
combinations 
• Further evaluate the role of vitamin B6 in people 
living with HIV. 
• Evaluate the efficacy and feasibility of long-term 
IPT in children.
• Study the efficacy of IPT in people with HIV and 
hepatitis C virus (HCV) coinfection.
• Determine the best regimen for and approach to 
IPT for those with drug-resistant or suspected to 
have drug-resistant M. tuberculosis.
• Outcomes of TB treatment for “breakthrough TB” 
in people living with HIV
• Optimal timing for initiation of IPT in relation to 
initiation of ART
• For those on lifelong IPT, is there value in 
discontinuing it after immune reconstitution?
• Interaction between IPT and other medications, 
particularly in the context of coinfection with viral 
hepatitis
• Modelling studies to estimate the risks and 
benefits of IPT – key considerations include 
the incidence and prevalence of HIV and TB, 
risk for TB by immune status, impact of ART on 
prevention of both HIV and TB, added benefit of 
IPT, optimum duration of IPT, prevalence of INH 
and rifampicin resistance, immune status, TST 
status. 
4.3 Operational research
• Potential limitations of IPT in populations with a 
high prevalence of INH-resistant TB
• Risks and benefits of administering INH (in error) 
to undiagnosed people with active TB
• Effectiveness of IPT programmes in resource-
limited settings; cost-effectiveness and cost–
benefit from the health systems and patients’ 
perspectives
• IPT and special populations: benefits of and 
duration for health-care workers living with HIV; 
frequency of screening; benefits for TST-negative 
health-care workers; HIV-exposed children
• How to operationalize short-term and lifelong IPT 
with a particular focus on monitoring programmes 
and individuals (i.e. clinical status and adherence)
• Population-based drug-resistance surveillance 
to determine the impact of IPT programmes on 
drug-resistant TB in the community, including 
increases or decreases in mono-INH and mono-
rifampicin resistance, and MDR TB
• Evaluate the best national programmes or 
services to lead the implementation of IPT (e.g. 
HIV, maternal and child health [MCH], TB, all 
programmes).
• Optimal delivery of IPT and other HIV care for 
special groups including women and children.
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What is the best combination of symptoms with or without radiology that can be used as a screening tool to identify 
people living with HIV who are eligible for treatment of LTBI and for diagnostic work-up for active TB?
Bibliography: Ayles et al. 2009; Corbett et al. 2010; Cain et al. 2010; Corbett et al. 2007; Lewis et al. 2009; Shah et al. 
2009; Kimerling et al. 2002; Lawn et al. 2009; Chheng et al. 2008; Getahun et al. (in press)
GRADE profile table 1: TB screening for adults and adolescents
0.97 (95% CI: 0.97, 0.98)
0.98 (95% CI: 0.97, 0.99)
0.79 (95% CI: 0.75, 0.82)
0.90 (95% CI: 0.66, 0.97) 
0.49 (95% CI: 0.29, 0.70)
0.38 (95% CI: 0.12, 0.73) 
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
8148 (9 studies)
2805 (4 studies)
8148 (9 studies)
2805 (4 studies)
8148 (9 studies)
2805 (4 studies)
Critical
Critical
Critical
Critical
Important
Important
Any one of current cough, fever, night sweats, weight loss as the best combination of symptoms for screening
Any one of current cough, fever, night sweats, weight loss or abnormal chest X-ray 
findings as the best combination of symptoms for screening
Negative predictive value
Negative predictive value
Specificity
Specificity
Sensitivity
Sensitivity
Values and uncertainty 
around these 
Quality of evidenceNumber of participants 
(studies)
Importance
6. Selected GRADE profiles
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Quality assessment
Quality 
assessment
Any one of cough ≥2 weeks, fever or  failure to thrive 
1
1
1
1
Serious
limitation*
Serious
limitation*
Serious
limitation*
Serious
limitation*
No serious 
indirectness 
No serious 
indirectness 
No serious 
indirectness 
No serious 
indirectness 
Observational 
study (303)
Observational 
study (303)
Observational 
study (303)
Observational 
study (303)
No serious 
inconsistency
No serious 
inconsistency
No serious 
inconsistency
No serious 
inconsistency
No serious 
imprecision#
No serious 
imprecision#
No serious 
imprecision#
No serious 
imprecision#
Low
Low
Low
Low
Negative predictive value 0.99
Specificity 0.65
Sensitivity 0.90
Positive predictive value 0.15
Design 
(number of 
participants)
Limitations Inconsistency Indirectness Other 
considerations
Imprecision Quality 
of evidence
GRADE profile table 2: TB screening for children
What is the best combination of symptoms and diagnostic tools that can be used as a screening tool to identify HIV-
infected children eligible for treatment of LTBI?
Bibliography: Song et al. 2009
A combination of culture and radiological appearance was used as a gold standard, which is not a perfect gold standard. The study 
did not qualify for the highest quality of evidence since it was an observational study and did not have a well-defined gold standard.
* The reference standard used is unlikely to correctly classify all the children with disease as having the disease. Moreover, sputum 
was collected only from children having signs and symptoms suggestive of TB or abnormal chest X-ray findings.  
# Confidence intervals for sensitivity and specificity were not reported. 
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GRADE profile table 3: Efficacy of INH vs placebo in persons with any TST status
Bibliography: Pape et al. 1993; Whalen et al. 1997; Hawken et al. 1997; Mwinga et al. 1998; Fitzgerald et al. 2001; 
Gordin et al. 1997; Rivero et al. 2003; Whalen et al.1997 – anergy
8
5
7
No serious
limitations
No serious
limitations
No serious
limitations
No serious
indirectness 
No serious
indirectness 
No serious
indirectness 
None
None
None
Randomized trials
Randomized trials
Randomized trials
No serious
inconsistency1
No serious
inconsistency
Serious2
No serious 
imprecision
No serious 
imprecision
No serious 
imprecision
Active TB incidence (probable, possible, confirmed) (follow up 1–3 years; clinical examination, chest X-ray, sputum for AFB)
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
Active TB incidence (probable, possible, confir ed) (fo low up 1–3 years; clinical exa ination, chest X-ray, sputu  for AFB)
Confirmed TB (follow up 1–3 years; culture-proven)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
2
7
No serious
limitations
No serious
limitations
No serious
indirectness 
No serious
indirectness 
None
None
Randomized trials
Randomized trials
Serious2
No serious
inconsistency
No serious 
imprecision
No serious 
imprecision
1 Three out of 8 studies showed an opposite direction of the effect 2 Different direction of the effect across the studies
HIV disease progression (follow up 1-3 years; clinical and immunological criteria)
Adverse drug reaction leading to treatment interruption (follow up 1–3 years; clinical and laboratory monitoring)
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Active TB incidence (probable, possible, confirmed) (follow up 1–3 years; clinical examination, chest X-ray, sputum for AFB)Active TB incidence (probable, possible, confir ed) (fo low up 1–3 years; clinical exa ination, chest X-ray, sputu  for AFB)
Confirmed TB (follow up 1–3 years; culture-proven)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
HIV disease progression (follow up 1-3 years; clinical and immunological criteria)
Adverse drug reaction leading to treatment interruption (follow up 1–3 years; clinical and laboratory monitoring)
85/2152 (3.9%)
34/1037 (3.3%)
427/2152 (19.8%)
RR 0.67 (0.51–0.87)
RR 0.72 (0.47–1.11)
RR 0.95 (0.85–1.06)
HIGH
HIGH
      O
MODERATE
123/1984 (6.2%)
123/1984 (6.2%)
419/1984 (21.1%)
2%
2%
5%
7 fewer per 1000
(from 3 fewer 
to 10 fewer)
6 fewer per 1000
(from 11 fewer 
to 2 more)
3 fewer per 1000
(from 7 fewer 
to 3 more)
50%
50%
50%
165 fewer per 1000 
(from 65 fewer 
to 245 fewer)
140 fewer per 1000 
(from 265 fewer 
to 55 more)
25 fewer per 1000
(from 75 fewer 
to 30 more)
20 fewer per 1000
(from 8 fewer 
to 30 fewer)
13 fewer per 1000
(from 24 fewer 
to 5 more)
11 fewer per 1000
(from 32 fewer 
to 13 more)
CRITICAL
CRITICAL
CRITICAL
No. of patients Effect
Summary of findings
INH prophylaxis Control Relative risk
(95% CI)
Absolute Quality
Importance
41/184 (22.3%)
56/2026 (2.8%)
RR 0.88 (0.6–1.28)
RR 1.66 (1.09–2.51)
        O
MODERATE
HIGH
43/171 (25.1%)
33/1873 (1.8%)
10%
0%
12 fewer per 1000
(from 40 fewer to 28 
more)
0 more per 1000
(from 0 more to 0
more)
50%
20%
60 fewer per 1000
(from 200 fewer 
to 140 more)
132 more per 1000 
(from 18 more to 302 
more)
30 fewer per 1000
(from 101 fewer to 70 
more)
12 more per 1000
(from 2 more to 27 
more)
CRITICAL
CRITICAL
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Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
GRADE profile table 4: Efficacy of INH vs placebo in persons who are TST positive
Bibliography: Pape et al. 1993; Whalen et al. 1997; Hawken et al. 1997; Mwinga et al. 1998
4 No serious
limitations
No serious
indirectness 
NoneRandomized trials No serious
inconsistency
No serious 
imprecision
Active TB incidence (probable, possible, confirmed) (follow up 1-3 years; clinical examination, chest X-ray, sputum for AFB)
1
3
1
No serious
limitations
No serious
limitations
No serious
limitations
No serious
indirectness 
No serious
indirectness 
No serious
indirectness 
None
None
None
Randomized trials
Randomized trials
Randomized trials
Serious1
No serious
inconsistency3
Serious1
Serious2
No serious 
imprecision
No serious 
imprecision
1 Only one study available to address this outcome
2 Small sample size and wide CI
3 Mwinga et al. report an opposite direction of the effect
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Active TB incidence (possible, pr bable, confir ed) (fol ow up 1–
HIV disease progression (follow up 1–3 years; clinical and immunological criteria)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
Confirmed TB (follow up 1–3 years; culture-proven)
Active TB incidence (probable, possible, confirmed) (follow up 1-3 years; clinical examination, chest X-ray, sputum for AFB)
No. of patients Effect
Summary of findings
INH prophylaxis Control Relative risk
(95% CI)
Absolute Quality
Importance
18/693 (2.6%) RR 0.36 (0.22–0.61)
HIGH
46/618 (7.4%)
2% 13 fewer per 1000
(from 8 fewer to 16 
fewer)
50% 320 fewer per 1000 
(from 195 fewer to 
390 fewer)
48 fewer per 1000
(from 29 fewer to 58 
fewer)
CRITICAL
0/52 (0%)
71/693 (10.2%)
6/11 (54.5%)
RR 0.13 (0.01–2.32)
RR 0.74 (0.55–1)
RR 0.36 (0.15–0.85)
     OO
LOW
HIGH
          O
MODERATE
4/60 (6.7%)
84/618 (13.6%)
38/25 (152%)
2%
2%
10%
17 fewer per 1000
(from 20 fewer to 26 
more)
5 fewer per 1000
(from 9 fewer to 0 
more)
64 fewer per 1000
(from 15 fewer to 85 
fewer)
50%
50%
50%
435 fewer per 1000 
(from 495 fewer to 
660 more)
130 fewer per 1000 
(from 225 fewer to 0 
more)
320 fewer per 1000 
(from 75 fewer 
to 425 fewer)
58 fewer per 1000
(from 66 fewer to 88 
more)
35 fewer per 1000
(from 61 fewer to 0 
more)
973 fewer per 1000 
(from 228 fewer to
1292 fewer)
CRITICAL
CRITICAL
CRITICAL
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Active TB incidence (possible, pr bable, confir ed) (fol ow up 1–
HIV disease progression (follow up 1–3 years; clinical and immunological criteria)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
Confirmed TB (follow up 1–3 years; culture-proven)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
GRADE profile table 5: Efficacy of INH vs placebo in persons who are TST negative
Bibliography: Fitzgerald et al. 2001; Gordin et al. 1997; Hawken et al. 1997; Mwinga et al. 1998; Pape et al. 1993; 
Rivero et al. 2003; Whalen et al.1997– anergy
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
7
3
7
No serious
limitations
No serious
limitations
No serious
limitations
No serious
indirectness 
No serious
indirectness 
No serious
indirectness 
None
None
None
Randomized trials
Randomized trials
Randomized trials
No serious
inconsistency1
Serious2
No serious 
inconsistency
No serious 
imprecision
No serious 
imprecision
No serious 
imprecision
Active TB incidence (probable, possible, confirmed) (follow up 1-3 years; clinical examination, chest X-ray, sputum for AFB)
2 No serious
limitations
No serious
indirectness 
NoneRandomized trials Serious3 No serious 
imprecision
1 Fitzgerald et al. and Hawken et al. showed an opposite direction of the effect
2 Different direction of the effect across studies
3 Opposite direction of the effect
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Active TB (possible, probable, confirmed) (follow up 1–3 years; clinical examination, chest X-ray, sputum for AFB)
Confirmed TB (follow up 1–3 years; culture-proven)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
HIV disease progression (follow up 1–3 years; clinical and immunological criteria)
Active TB incidence (probable, possible, confirmed) (follow up 1-3 years; clinical examination, chest X-ray, sputum for AFB)
No. of patients Effect
Summary of findings
INH prophylaxis Control Relative risk
(95% CI)
Absolute Quality
Importance
49/1297 (3.8%)
12/521 (2.3%)
328/1297 (25.3%)
RR 0.86 (0.59–1.26)
RR 0.76 (0.36–1.61)
RR 1.02 (0.9–1.16)
HIGH
       O
MODERATE
HIGH
54/1193 (4.5%)
15/500 (3%)
298/1193 (25%)
2%
2%
2%
3 fewer per 1000
(from 8 fewer to 5 
more)
5 fewer per 1000
(from 13 fewer to 12 
more)
0 more per 1000
(from 2 fewer to 3 
more)
50%
50%
50%
70 fewer per 1000
(from 205 fewer to
130 more)
120 fewer per 1000 
(from 320 fewer to
305 more)
10 more per 1000
(from 50 fewer to 80 
more)
6 fewer per 1000
(from 19 fewer to 12 
more)
7 fewer per 1000
(from 19 fewer 
to 18 more)
5 more per 1000
(from 25 fewer to 40 
more)
CRITICAL
CRITICAL
CRITICAL
35/146 (24%) RR 1.10 (0.72–1.69)        O
MODERATE
32/146 (21.9%)
10% 10 more per 1000
(from 28 fewer to 69 
more)
50% 50 more per 1000
(from 140 fewer to
345 more)
22 more per 1000
(from 61 fewer 
to 151 more)
CRITICAL
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Active TB (possible, probable, confirmed) (follow up 1–3 years; clinical examination, chest X-ray, sputum for AFB)
Confirmed TB (follow up 1–3 years; culture-proven)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
HIV disease progression (follow up 1–3 years; clinical and immunological criteria)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
GRADE profile table 6: Efficacy of INH vs placebo in persons with unknown TST status 
Bibliography: Mwinga et al. 1998; Hawken et al. 1997
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
2
2
No serious
limitations
No serious
limitations
No serious
indirectness 
No serious
indirectness 
None
None
Randomized trials
Randomized trials
Serious1
No serious 
inconsistency
No serious 
imprecision
No serious 
imprecision
2 No serious
limitations
No serious
indirectness 
None
None
Randomized trials No serious 
inconsistency
No serious 
imprecision
1 Opposite direction of the effect
0 No evidence 
available
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Active TB incidence (probable, possible, confirmed) (follow up 1–3 years; clinical examination, chest X-ray, sputum for AFB)
Confirmed TB (follow up 1–3 years; culture-proven)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
HIV disease progression (follow up 1–3 years; clinical and immunological criteria)
GRADE profile table 6: Efficacy of INH vs placebo in persons with unknown TST status 
No. of patients Effect
Summary of findings
INH prophylaxis Control Relative risk
(95% CI)
Absolute Quality
Importance
18/162 (11.1%)
22/464 (4.7%)
RR 0.86 (0.48–1.52)
RR 0.79 (0.46–1.36)
        O
MODERATE
HIGH
23/173 (13.3%)
28/466 (6%)
2%
2%
3 fewer per 1000
(from 10 fewer to 10 
more)
4 fewer per 1000
(from 11 fewer to 7 
more)
50%
50%
70 fewer per 1000
(from 260 fewer to
260 more)
105 fewer per 1000 
(from 270 fewer to
180 more)
19 fewer per 1000
(from 69 fewer to 69 
more)
13 fewer per 1000
(from 32 fewer to 22 
more)
CRITICAL
CRITICAL
28/162 (17.3%)
0/0 (0%)
RR 0.81 (0.52–1.27)
RR 0 (0–0)
HIGH
37/173 (21.4%)
0/0 (0%)
2%
0%
4 fewer per 1000
(from 10 fewer to 5 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
50% 95 fewer per 1000
(from 240 fewer to
135 more)
41 fewer per 1000
(from 103 fewer to
58 more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
CRITICAL
CRITICAL
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Active TB incidence (probable, possible, confirmed) (follow up 1–3 years; clinical examination, chest X-ray, sputum for AFB)
Confirmed TB (follow up 1–3 years; culture-proven)
Mortality (any cause) (follow up 1–3 years; review of hospital records)
HIV disease progression (follow up 1–3 years; clinical and immunological criteria)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
GRADE profile table 7: Duration of IPT in adults – INH 6 months vs 36 months
Bibliography: Martinson et al.2009; Samandari et al. 2009
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
2 No serious
limitations1
Serious2, 3, 4 NoneRandomized trials No serious
inconsistency
No serious 
imprecision
1
2
2
05
No serious
limitations
No serious
limitations1
No serious
limitations
Serious
Serious2, 3, 4
No serious 
indirectness
None
None
None
None
Randomized trials
Randomized trials
Randomized trials
No evidence 
available
No serious 
inconsistency
No serious
inconsistency
Serious6
No serious 
imprecision
No serious 
imprecision
No serious 
imprecision
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Active TB incidence (probable, possible, confirmed) (follow up mean 36 months; clinical assessment, chest X-ray, sputum for AFB)
Adverse drug reactions leading to treatment interruption (follow up 36 months; laboratory monitoring and clinical assessment)
HIV disease progression
Mortality (any cause) (follow up 36 months; review of hospital records and patients’ files)
Confirmed TB (follow up mean 36 months; culture-proven)
1 The Soweto trial was not a head-to-head comparison but a four-arm study designed to compare the efficacy of different regimens as well.
2 The Soweto trial considered TST-positive patients while the BOTUSA trial enrolled TST-positive and -negative patients.
3 Mean CD4 count at baseline was >500 cells/mm3 for the Soweto trial and around 200 cells/mm3 for the BOTUSA trial.
4 The Soweto trial enrolled patients not eligible for ART, while in the Botusa trial about 40% of the patients had started ART.
5 Subanaylsis on this outcome is expected to be performed soon.
6 The number of the affected is quite different between studies.
No. of patients Effect
Summary of findings
Continuous INH 
prophylaxis
6 months INH
prophylaxis
Relative risk
(95% CI)
Absolute Quality
Importance
20/997 (2%) RR 0.50 (0.29–0.84)         O
MODERATE
46/1150 (4%)
2% 10 fewer per 1000
(from 3 fewer to 14 
fewer)
50% 250 fewer per 1000 
(from 80 fewer to 355 
fewer)
20 fewer per 1000
(from 6 fewer to 28 
fewer)
CRITICAL
14/997 (1.4%)
15/997 (1.5%)
70/983 (7.1%)
0/0 (0%)
RR 0.48 (0.26–0.9)
RR 0.43 (0.24–0.78)
RR 5.02 (2.74–9.198)
RR 0 (0–0)
       O
MODERATE
         O
MODERATE
         O
MODERATE
33/1150 (2.9%)
40/1150 (3.5%)
12/846 (1.4%)
0/0 (0%)
2%
10%
1%
0%
10 fewer per 1000
(from 2 fewer to 15 
fewer)
57 fewer per 1000
(from 22 fewer to 76 
fewer)
40 more per 1000
(from 17 more to 82 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
50%
50%
260 fewer per 1000 
(from 50 fewer to 370 
fewer)
285 fewer per 1000 
(from 110 fewer to
380 fewer)
15 fewer per 1000
(from 3 fewer to 21 
fewer)
20 fewer per 1000
(from 8 fewer to 26 
fewer)
57 more per 1000
(from 25 more to 116 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
CRITICAL
CRITICAL
CRITICAL
CRITICAL
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Selected GRADE profiles
Active TB incidence (probable, possible, confirmed) (follow up mean 36 months; clinical assessment, chest X-ray, sputum for AFB)
Adverse drug reactions leading to treatment interruption (follow up 36 months; laboratory monitoring and clinical assessment)
HIV disease progression
Mortality (any cause) (follow up 36 months; review of hospital records and patients’ files)
Confirmed TB (follow up mean 36 months; culture-proven)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
GRADE profile table 8: Duration of IPT in adults INH 6 months vs 12 months 
in those with any TST status
Bibliography: Pape et al. 1993; Whalen et al. 1997; Hawken et al. 1997; Mwinga et al. 1998; Fitzgerald et al. 2001; Gordin 
et al. 1997; Rivero et al. 2003; Whalen et al.1997 – anergy
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
8
0
2
Very serious
Very serious
No serious
indirectness 
No serious
indirectness 
None
None
None
Randomized trials
No evidence 
available
Randomized trials
No serious
inconsistency
No serious 
inconsistency
No serious 
imprecision
No serious 
imprecision
0
12
NoneNo evidence 
available
Very serious No serious
indirectness 
NoneRandomized trials No serious 
inconsistency
No serious 
imprecision
1 Not estimable due to the lack of events in the 12 months’ group.
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Mortality (any cause) (follow up 1–3 years; review of hospital records and patients’ files)
Active TB--possible, probable, confirmed (follow up 1–3 years; clinical assessment, chest X-ray, sputum for AFB)
Adverse drug reactions leading to treatment interruption  (follow up 1–3 years; laboratory monitoring and clinical assessment)
HIV disease progression 
Confirmed TB (follow up 1–3 years; culture-proven)
No. of patients Effect
Summary of findings
6 months of INH 
prophylaxis
12 months of INH 
prophylaxis
Relative risk
(95% CI)
Absolute Quality
Importance
57/1806 (3.2%)
0/0 (0%)
375/1806 (20.8%)
RR 0.58 (0.3–1.12)
RR 0 (0–0)
RR 1.59 (1.085–2.34)
      OO
LOW
      OO
LOW
10/184 (5.4%)
0/0 (0%)
24/184 (13%)
2%
0%
10%
8 fewer per 1000
(from 14 fewer to 2 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
59 more per 1000
(from 9 more to 134 
more)
50%
0%
50%
210 fewer per 1000 
(from 350 fewer to 60 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
295 more per 1000 
(from 43 more to 670 
more)
23 fewer per 1000
(from 38 fewer to 7 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
77 more per 1000
(from 11 more to 175 
more)
CRITICAL
CRITICAL
CRITICAL
0/0 (0%)
56/1968 (2.8%)
RR 0 (0–0)
RR 0 (0–0)1
0/0 (0%)
0/58 (0%)
0%
0%
0 fewer per 1000
(from 0 fewer to 0 
fewer)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
CRITICAL
CRITICAL     OO
LOW
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Mortality (any cause) (follow up 1–3 years; review of hospital records and patients’ files)
Active TB--possible, probable, confirmed (follow up 1–3 years; clinical assessment, chest X-ray, sputum for AFB)
Adverse drug reactions leading to treatment interruption  (follow up 1–3 years; laboratory monitoring and clinical assessment)
HIV disease progression 
Confirmed TB (follow up 1–3 years; culture-proven)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
GRADE profile table 9: Efficacy in children – INH 6 months vs placebo 
Bibliography: Zar et al. 2007; Madhi et al. 2008
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
2
1
No serious
limitations
No serious
limitations
No serious
indirectness2
No serious
indirectness 
None
None
Randomized trials
Randomized trials
Serious1
Serious3
No serious 
imprecision
Serious4
2
2
0
NoneRandomized trials
No serious 
limitations
No serious 
limitations
No serious 
indirectness5
No serious 
indirectness2
None
None
Randomized trials No serious 
inconsistency
Serious1
No serious 
imprecision
No serious 
imprecision
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Confirmed TB (follow up 5.7–9 months; culture-proven)
Active TB (follow up 5.7–9 months; clinical algorithm criteria, chest X-ray, bacteriological isolates from any site)
HIV disease progression
Adverse reaction (grade 3 or 4 toxicity) (follow up 5.7–9 months; clinical and laboratory monitoring)
Mortality (all causes) (follow up 5.7–9 months; review of hospital records and patients’ files)
1 Opposite direction of the effect.
2 P1041 represents an optimal HIV care setting, with good facilities to rule out active TB: children were younger, healthier and 
presented in a less advanced stage of disease; the study by Zar et al. represents the most common condition of rural areas with later 
diagnosis of TB, fewer resources, and children presenting with more advanced disease and challenging TB diagnosis.
3 One trial available
4 Wide confidence intervals
5 Raw data are missing for P1041 (but no significant difference was reported between the two groups).
GRADE profile table 9: Efficacy in children – INH 6 months vs placebo 
No. of patients Effect
Summary of findings
INH prophylaxis
(6 months)
Placebo Relative risk
(95% CI)
Absolute Quality
Importance
44/358 (12.3%)
3/226 (1.3%)
RR 0.97 (0.6609–
1.4384)
RR 1.5 (0.25–8.89)
      O
MODERATE
      OO
LOW
45/357 (12.6%)
3/226 (1.3%)
5%
0.9%
1 fewer per 1000
(from 17 fewer to 22 
more)
4 more per 1000
(from 7 fewer to 71 
more)
4 fewer per 1000
(from 43 fewer to 55 
more)
7 more per 1000
(from 10 fewer to 105 
more)
CRITICAL
CRITICAL
26/358 (7.3%)
5/132 (3.8%)
0/0 (0%)
RR 0.84 (0.51–1.37)
RR 0.62 (0.21–1.85)
RR 0 (0–0)
31/357 (8.7%)
8/131 (6.1%)
0/0 (0%)
10%
0%
0%
16 fewer per 1000
(from 49 fewer to 37 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
14 fewer per 1000
(from 43 fewer to 32 
more)
23 fewer per 1000
(from 48 fewer to 52 
more)
0 fewer per 1000
(from 0 fewer to 0 
fewer)
CRITICAL
CRITICAL
CRITICAL
HIGH
       O
MODERATE
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Confirmed TB (follow up 5.7–9 months; culture-proven)
Active TB (follow up 5.7–9 months; clinical algorithm criteria, chest X-ray, bacteriological isolates from any site)
HIV disease progression
Adverse reaction (grade 3 or 4 toxicity) (follow up 5.7–9 months; clinical and laboratory monitoring)
Mortality (all causes) (follow up 5.7–9 months; review of hospital records and patients’ files)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
GRADE profile table 10: Drug resistance and use of preventive therapy 
Bibliography: Hawken 1997; Johnson et al. 2001; Pape et al. 1993; Rivero et al. 2003; Saenghirunvatta 1996; Zar et al. 
2007; le Roux et al. 2009; Mwinga et al. 1998; Halsey et al. 1998; Gordin et al. 2000
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
Quality assessment
No. of
studies
Design Limitations Inconsistency Indirectness Other 
considerations
Imprecision
1 Incomplete accounting of patients and outcomes
2 Small number of cases and patients
3 Small number of patients
7
3
Serious1
Serious1
No serious
indirectness
No serious
indirectness 
None
None
Randomized trials
Randomized trials
No serious 
inconsistency
No serious 
inconsistency
Serious2
Very serious3
1 The study by Perriens et al. provided INH and rifampicin for six months instead of INH alone.
2 Small numbers in study
Bibliography: Perriens et al. 1995; Haller et al. 1999; Fitzgerald et al. 2000; Churchyard et al. 2003
1
3
Serious
No serious 
limitations
Serious
No serious
indirectness1
Strong association
None
Observational
study
Randomized trials
No serious 
inconsistency
No serious 
inconsistency
No serious 
imprecision
Serious2
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GRADE profile table 11: Secondary prophylaxis
Mono-resistance to INH vs rifampicin (IPT intervention vs rifampicin as control)
Mono-resistance to INH vs placebo (IPT intervention vs placebo)
TB recurrence (observational) (follow up 0.91 vs 0.41 patient-years; isoniazid vs co-trimoxazole)
TB recurrence (randomized)
No. of patients Effect
Summary of findings
Anti-TB
medications
No medications Relative risk
(95% CI)
Absolute Quality
Importance
No. of patients Effect
Summary of findings
Secondary
treatment of LTBI
Control Relative risk
(95% CI)
Absolute Quality
Importance
11/1255(0.9%)
3/1469 (0.2%)
RR 1.87 
(0.65–5.38)
RR 2 
(0.18–22.03)
      O
MODERATE
  OOO
VERY LOW
5/1069 (0.5%)
1/1469 (0.1%)
4 more per 1000
(from 2 fewer to 20 
more)
1 more per 1000
(from 1 fewer to 14 
fewer)
CRITICAL
LESS CRITICAL
28/338 (8.3%)
7/275 (2.5%)
RR 0.45 (0.26–0.78)
RR 0.23 (0.11–0.52)
23/221 (10.4%)
31/286 (10.8%)
57 fewer per 1000
(from 23 fewer to 77 
fewer)
83 fewer per 1000
(from 52 fewer to 96 
fewer)
CRITICAL
LESS CRITICAL      O
MODERATE
  OOO
VERY LOW
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Mono-resistance to INH vs rifampicin (IPT intervention vs rifampicin as control)
Mono-resistance to INH vs placebo (IPT intervention vs placebo)
TB recurrence (observational) (follow up 0.91 vs 0.41 patient-years; isoniazid vs co-trimoxazole)
TB recurrence (randomized)
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings
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Guidelines for intensified tuberculosis case-finding 
and isoniazid preventive therapy 
for people living with HIV 
in resource-constrained settings
Tuberculosis (TB) is responsible for more than a quarter of deaths in people living with 
HIV. Isoniazid Preventive Therapy (IPT) and Intensified tuberculosis Case-Finding 
(ICF) are key public health interventions that significantly reduce the morbidity and 
mortality from TB in people living with HIV. IPT and ICF should be part of a TB 
prevention package along with infection control for TB and the provision of ART. 
The objective of these guidelines is to provide guidance to national AIDS and 
tuberculosis programmes and those providing HIV services to accelerate the nationwide 
implementation of IPT and ICF. They include evidence-based recommendations 
for adults, children and infants living with HIV, address implementation issues 
and identify key research gaps in order to scale up TB prevention, diagnosis 
and treatment as a core component of HIV prevention, treatment and care. They 
are aimed at policy-makers and health programme managers, governments, 
nongovernmental organizations, donors, patient support groups working in the field of 
HIV/AIDS and TB, and health-care workers providing care for people living with HIV.
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